(CNN)The US Food and Drug Administration has rejected a submission from Phoenix Biotechnology Inc. to market oleandrin as a dietary supplement ingredient, citing “significant concerns” about the safety evidence the company presented.
Last month, MyPillow CEO Mike Lindell, who recently joined the board of Phoenix Biotechnology and has a financial stake in the company, said he had participated in a July meeting at the White House with President Donald Trump regarding the use of oleandrin as a potential therapeutic for the coronavirus. The extract comes from the Nerium oleander plant; the raw oleander plant is highly toxic and consuming it can be fatal. There are no peer-reviewed, published studies on the impact of oleandrin on Covid-19, and there’s no public evidence it has been studied in patients with Covid-19.White House focus on oleandrin treatment for coronavirus would be 'nonsense,' experts sayOn June 2, Phoenix Biotechnology submitted oleandrin to the FDA as a new ingredient in dietary supplements, describing the dosage and saying it’s intended only for adults. If a dietary supplement contains a new ingredient, manufacturers must notify the FDA, and the agency will review it for safety — not effectiveness — and determine whether it may be marketed as a dietary supplement.The FDA’s response letter, dated August 14, was posted by the agency on Wednesday. It said the company had already tested oleandrin as a potential prescription drug and could not at the same time seek permission to sell it as a supplement — a category with almost no oversight.Read MoreEven if it hadn’t been excluded from the definition of a dietary supplement under the law, the agency had “significant concerns about the evidence included in your submission as a basis for concluding that a dietary supplement containing ‘Oleandrin’ will reasonably be expected to be safe” if used the way the company described.Trump 'enthusiastic' over unproven coronavirus therapeutic, MyPillow creator says The FDA said Phoenix Biotechnology provided evidence of a history of medicinal use of Nerium oleander extracts and some evidence of preclinical and clinical studies, but the safety evidence was not “qualitatively and quantitatively” related to oleandrin as a supplement.”Studies performed in advanced cancer patients generally cannot establish the safety of your ingredient in its intended population of normal healthy adults, and you did not provide any information to indicate that such extrapolation between different populations would be scientifically valid,” the FDA’s letter said.The FDA’s letter did not mention using the extract as a treatment for Covid-19.Lindell, who has no scientific background or medical training, has said previously he was so enthusiastic about the product as a Covid-19 treatment that he had started taking the extract as a prophylactic and has encouraged his friends to do the same. He had brought his research to Housing and Urban Development Secretary Dr. Ben Carson, a member of the White House Coronavirus Task Force. Lindell said in July that Carson was “just amazed,” and thought “it was very exciting seeing all the data.”After Lindell met with Trump in July, he described the President’s response to the extract as “enthusiastic.” Lindell told CNN in July that Trump wanted the FDA to “do its course.” When asked about the extract in August, Trump said he had “heard about” oleandrin and said, “We’ll look at it, we’ll look at it, we’re looking at a lot of different things.” It’s unclear if Trump raised the issue with the FDA.